Topiramate in Epilepsy: Higher Glaucoma Risk in Women

Research Summary

A new study published in Epilepsia reveals that the epilepsy drug topiramate is linked to a higher risk of developing glaucoma compared to other antiseizure medications, valproate and lamotrigine. Researchers found that within one year, the absolute risk increase for glaucoma was about 2% to 2.4% for topiramate users. The risk was notably higher in female and epilepsy patients, with adjusted hazard ratios indicating a more than fivefold increase in risk for females compared to both valproate and lamotrigine users. However, no significant risk was found in male or migraine patients. These insights could guide ophthalmologic monitoring in high-risk groups.

Study Details

📄 Title: Sex-specific elevated incidence of glaucoma associated with topiramate versus valproate or lamotrigine in epilepsy, not migraine: A population-based cohort study.

👥 Research Team: Wei C et al.

📚 Published In: Epilepsia

📅 Publication Date: 2026 Jan 10

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.